Vadadustat
Vadadustat (PG-1016548) is a titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor[1]. Vadadustat is an erythropoiesis-stimulating agent and has the potential for anemia treatment in chronic kidney disease in vivo[1][2].
Product Specifications
CAS Number
1000025-07-9
Product Name Alternative
PG-1016548; AKB-6548
UNSPSC
12352005
Hazard Statement
H303, H320
Target
HIF/HIF Prolyl-Hydroxylase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/Vadadustat.html
Concentration
10mM
Purity
99.83
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(O)CNC(C1=NC=C(C2=CC=CC(Cl)=C2)C=C1O)=O
Molecular Formula
C14H11ClN2O4
Molecular Weight
306.70
Precautions
H303, H320
References & Citations
[1]Pergola PE, et al. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int. 2016 Nov;90 (5) :1115-1122.|[2]Gupta N, et al. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD. Am J Kidney Dis. 2017 Feb 24. pii: S0272-6386 (17) 30110-5.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LY422283 100 µg
HNF 4 alpha (HNF4A) (NM_001030003) Human Over-expression Lysate
Sign In for Pricing
View Details 
BNC402978-100 1x 100 µL
Cyclin B1 (G2- & M-phase Cyclin) (CCNB1/2978R), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC682784-100 1x 100 µL
AKT1 (Prognostic Marker for Neuroendocrine Tumors) (AKT1/2784), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details